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The Late Endosomal Adaptor Molecule p14
(LAMTOR2) Regulates TGFb1-Mediated Homeostasis
of Langerhans Cells
Florian Sparber1,4, Christoph H. Tripp1, Kerstin Komenda1, Julia M. Scheffler2, Bjo¨rn E. Clausen3,
Lukas A. Huber2, Nikolaus Romani1 and Patrizia Stoitzner1
Langerhans cells (LCs), a sub-population of dendritic cells (DCs) in the skin, participate in the regulation of
immunity and peripheral tolerance. The adaptor molecule p14 is part of the late endosomal/lysosomal adaptor
and mitogen-activated protein kinase and mammalian target of rapamycin (mTOR) activator/regulator (LAMTOR)
complex, which mediates the activation of lysosome-associated extracellular signaling–regulated kinase (ERK) and
the mTOR cascade. In previous work, we demonstrated that CD11c-specific deficiency of p14 disrupts LC
homeostasis by affecting the LAMTOR-mediated ERK and mTOR signaling. In this study, we extended our analysis
on p14 deficiency specifically in LCs. Langerin-specific ablation of p14 caused a complete loss of LCs,
accompanied by an increased maturational phenotype of LCs. The absence of LCs in p14-deficient mice reduced
contact hypersensitivity (CHS) responses to the contact sensitizer trinitrochlorobenzene. Analysis using bone
marrow–derived DCs (BMDCs) revealed that p14 deficiency in DCs/LCs interfered with the LC-relevant
transforming growth factor b1 (TGFb1) pathway, by lowering TGFb receptor II expression on BMDCs and LCs,
as well as surface binding of TGFb1 on BMDCs. We conclude that p14 deficiency affects TGFb1 sensitivity of LCs,
which is mandatory for their homeostasis and subsequently for their immunological function during CHS.
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INTRODUCTION
Langerhans cells (LCs) are resident dendritic cells (DCs) in the
epidermis of the skin and have been shown to participate in
the induction of immunity, as well as peripheral tolerance
(Merad et al., 2008; Romani et al., 2010). To do so, they need
to ingest, process, and finally present foreign antigen, as well
as self-antigen, bound to major histocompatibility complex
(MHC) molecules to T cells. A prerequisite for antigen
presentation is an efficient, intracellular endosomal sorting
machinery, which is controlled by several proteins including
adaptor and scaffold molecules.
Among others, the adaptor molecule p14, also termed late
endosomal/lysosomal adaptor and mitogen-activated protein
kinase (MAPK) and mammalian target of rapamycin (mTOR)
activator/regulator complex 2 (LAMTOR2), regulates endoso-
mal rearrangement, as well as other fundamental cellular
processes such as growth factor signaling and proliferation in
nonimmune but also immune cells (Teis et al., 2006;
Taub et al., 2012). More importantly, deficiency of p14 is
the molecular cause for the development of a hitherto
unknown primary human immunodeficiency syndrome,
which displays hallmarks reminiscent of diseases such
as Griscelli and Hermansky–Pudlak syndrome (Klein et al.,
1994; Dell’Angelica et al., 1999; Me´nasche´ et al., 2000; Jung
et al., 2006). Recent work demonstrated that p14 exerts its
function by participating in the formation of the LAMTOR
complex, which consists of five adaptor and scaffolding
molecules: p18 (LAMTOR1), p14 (LAMTOR2), MP1
(LAMTOR3), HPXIP (LAMPTOR4), and C7orf59 (LAMTOR5).
The LAMTOR complex represents the signaling platform
important for the correct spatiotemporal activation of the
extracellular signal–regulated kinase (ERK) MAPK, as well as
the mTORC1 pathways at the stage of multivesicular
bodies and lysosomes (Wunderlich et al., 2001; Teis et al.,
2002; Nada et al., 2009; Sancak et al., 2010; Magee and
Cygler, 2011; Bar-Peled et al., 2012).
In previous work (Sparber et al., 2014), we identified
p14 as an important regulator for LC homeostasis, as its
CD11c-specific deletion led to a virtually complete loss of
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LCs in p14-deficient mice. This was mainly owing to increased
apoptosis and cell cycle arrest of LCs. At the molecular level,
we determined that the p14-mediated disruption of the
LAMTOR complex and the subsequently impaired ERK and
mTOR signaling caused the loss of LCs. However, because of
the pivotal function of p14 in regulating growth factor
signaling, we sought to extend our previous findings and
further investigated p14 deficiency in LCs with special focus
on the LC-relevant transforming growth factor b1 (TGFb1)
signaling pathway.
RESULTS
Langerin-specific deletion of p14 leads to a loss of Langerinþ
migratory DCs in the draining lymph nodes (LNs) of adult mice
Recently, we demonstrated that genetic deletion of the
adaptor molecule p14 under the control of the cd11c
promoter (CD11c-p14del mice) resulted in a complete loss of
epidermal LCs. To further investigate p14 deficiency in LCs,
we now specifically deleted p14 under the control of the
langerin/CD207 promoter by using Langerin-Cre mice (Zahner
et al., 2011) and analyzed the DC subsets in the skin-draining
LNs of adult Langerin-p14del and littermate control mice. LNs
of adult Langerin-p14del mice were of comparable size to
those of wild-type controls, and we could not detect any
significant differences in the percentages of total LN-resident
CD11chighMHC-class IIint DCs, nor in the various LN-resident
CD11cþCD4þCD8neg, CD11cþCD4negCD8þ , and CD11cþ
CD4negCD8neg DC subsets (Figure 1a and b). This held true for
mice of all ages analyzed, i.e., up to 2 months. In addition, no
difference in frequency of MHC-class IIlowCD11cþPDCA1þ
plasmacytoid DCs was observed (Figure 1a and c). In contrast,
we noticed a significantly reduced percentage of the CCR7þ
migratory CD11cintMHC-class IIhigh DC population in
Langerin-p14del as compared with control mice owing
to a marked reduction of the Langerinþ skin-derived DCs
(Figure 1a and d). Hence, our data demonstrate that langerin-
specific ablation of p14 resulted in a specific loss of Langerinþ
migratory DCs in the skin-draining LNs of Langerin-p14del
mice, which corroborates our previous observation concern-
ing the loss of Langerinþ migratory DCs after CD11c-specific
deletion of p14 (Sparber et al., 2014).
LCs are gradually lost in the skin of newborn Langerin-p14del
mice
Similar to the analysis of CD11c-p14del mice (Sparber et al.,
2014), we analyzed the skin of newborn Langerin-p14del and
control mice on defined time points after birth. In
concordance with our previous data, we observed a gradual
loss of epidermal LCs in Langerin-p14del mice. Intriguingly, we
could not detect any significant difference in the percentages
of LCs between Langerin-p14del and control mice during the
first week after birth, suggesting normal population of the
epidermis by LCs. However, p14-deficient LCs gradually
declined approximately at 3 weeks of age (Figure 2a, b, and
e). The delayed loss of LCs in the Langerin-p14del mice when
compared with CD11c-p14del mice (Sparber et al., 2014) can
be explained by the different expression kinetics of CD11c
and Langerin. Skin cell suspensions of newborn mice
contained MHC-class IIþ cells coexpressing CD11c; by day
3 after birth, most MHC-class IIþ cells were positive for
CD11c. In contrast, Langerin staining on MHC-class IIþ cells
was absent until day 7 after birth, when two-thirds of CD11cþ
cells coexpressed Langerin (Supplementary Figure S1 online).
Reminiscent of CD11c-p14del animals, the loss of LCs in
Langerin-p14del mice was accompanied by a more mature
phenotype of the cells, as indicated by elevated expression of
CD86 by LangerinþCD103 LCs from whole skin cell
suspensions (Figure 2c). At the same time, Langerin expression
decreased on LCs (Figure 2c). In addition, in pure epidermal
cell suspensions, we could confirm this enhanced maturation
of p14-deficient LCs, as these cells showed increased MFI of
CD86 and MHC-class II. As mentioned above, we noticed
MHC-class IIþLangerinlow cells besides the MHC-class IIþ
Langerinþ LC population (Figure 2f). Annexin-V revealed an
increased staining, indicating that Langerinlow cells could
represent apoptotic LCs that had partially lost Langerin and
MHC-class II expression (Supplementary Figure S2 online). In
contrast to LCs, we could not detect a reduction of Langerinþ
dermal DCs in Langerin-p14del mice (Figure 2d). This differs
from our observation in the skin of CD11c-p14del mice, which
displayed a significantly reduced frequency of Langerinþ
dermal DCs (Sparber et al., 2014).
In summary, our data demonstrate that langerin-specific
deletion of p14 leads to a gradual loss of LCs in situ starting 3
weeks after birth, which is accompanied by an increased
phenotypic maturation status of the LCs and decreased
expression of Langerin.
Absence of LCs in Langerin-p14del mice impairs contact
hypersensitivity (CHS) response
As the role of LCs in CHS remains controversial (Noordegraaf
et al., 2010; Romani et al., 2010), we assessed the
immunological consequence of the loss of LCs in Langerin-
p14del mice in the CHS response to the contact sensitizer
trinitrochlorobenzene (Picrylchlorid, TNCB). Langerin-p14del
and control mice were sensitized with 1% (high dose)
or 0.5% (low dose) TNCB on abdominal skin and 5 days
later they were challenged with either 0.5% (high dose) or
0.25% (low dose) on the ear skin, respectively (Figure 3a).
With both doses of TNCB, Langerin-p14del mice displayed
a significantly reduced ear swelling reaction 24hours
after TNCB challenge as compared with controls (Figure 3b).
Hence, our data demonstrate that the loss of LCs by
Langerin-specific ablation of p14 reduces TNCB-mediated
CHS responses, similar to animals with a selective
LC deficiency due to disrupted TGFb signaling (Zahner
et al., 2011).
CD11c-specific deletion of p14 impairs TGFb1-mediated
generation of LC-like bone marrow–derived DCs (LCL-BMDCs)
and facilitates their enhanced maturation
Analysis of the molecular mechanism of p14 deficiency in
CD11c-p14del BMDCs established that deletion of p14 leads
to a partial disruption of the ERK and mTORC1 signaling
pathway (Sparber et al., 2014). The latter pathway has already
been shown to affect LC homeostasis, as CD11c-specific
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deletion of the mTORC1-related regulatory-associated protein
of mTOR (RAPTOR) molecule led to a loss of LCs in situ
(Kellersch and Brocker, 2013). However, we observed an
increased maturation of p14-deficient LCs, which was not
apparent in RAPTOR-deficient mice (Kellersch and Brocker,
2013; Sparber et al., 2014). As TGFb1 is essential for the
development and homeostasis of LCs, as well as the
maintenance of the immature status of LCs in the epidermis
of LCs in the skin (Borkowski et al., 1997; Kaplan et al., 2007;
Kel et al., 2010), we hypothesized that p14 deficiency might
also affect TGFb1 signaling in LCs. It is, however, very difficult
to isolate sufficient amounts of highly purified LCs from the
skin of newborn mice (Chang-Rodriguez et al., 2005),
particularly from the declining pool of LCs in Langerin-
p14del mice. Therefore, we took advantage of BMDCs
obtained from CD11c-p14del and control mice. Bone
marrow precursors cultured in the presence of TGFb1 give
rise to a sub-population of Langerinþ LCL-BMDCs (LCL-
BMDCs) (Valladeau et al., 2002; Becker et al., 2011). We
first aimed to investigate the differentiation of these LCL-
BMDCs, using this approach as a readout for the TGFb1
sensitivity of p14-deficient BMDCs. It was therefore man-
datory to delete p14 at the earliest possible time point during
the bone marrow culture—that is, before the cells express
Langerin. Therefore, we performed these experiments with
CD11c-p14del mice, rather than with Langerin-p14del mice.
We investigated the effect of p14 deletion on the differentiation
of LCL-BMDCs in cultures supplemented with TGFb1 for 8
days. Intriguingly, significantly less LCL-BMDCs could be
generated from CD11c-p14del BM as compared with control
cultures, suggesting impaired TGFb1 signaling in p14-deficient
BDMCs. Furthermore, CD11c-p14del LCL-BMDCs exhibited
significantly elevated expression of the maturation marker
CD86 in terms of both percentage of positive cells and mean
fluorescence intensity (Figure 4a and b). Since a recent report
identified bone morphogenetic protein (BMP)7 as an important
factor for the differentiation of human LCs (Yasmin et al.,
2013), we tested its effect on the generation of LCL-BMDCs. In
contrast to TGFb1, the addition of BMP7 at various concen-
trations (50–200ngml–1) throughout the BMDC culture could
not induce differentiation of LCL-BMDCs in the murine system
(data not shown). The addition of TGFb1 to DC cultures
impairs the upregulation of maturation markers such as
MHC-class II, and CD86 by BMDCs (Strobl et al., 1997;
Yamaguchi et al., 1997; Geissmann et al., 1998; Caux et al.,
1999). We hypothesized that p14-deficient BMDCs are less
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sensitive to TGFb1 and thus more mature even in the presence
of abundant maturation-dampening TGFb1. Indeed, CD11cþ
BMDCs of CD11c-p14del mice, generated both in the presence
and absence of TGFb1 for 8 days, showed an increased
expression of the maturation markers MHC-class II, CD86,
and CD40 (Figure 4c and d). The inferiority of CD11c-p14del
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BMDCs to induce TGFb1-mediated LCL-BMDCs, combined
with increased expression of MHC-class II, CD86, and CD40
in cultures supplemented with TGFb1 is reminiscent of the
phenotype of Langerin-p14del LCs in vivo. These findings
suggest that p14 deletion affects TGFb1 responsiveness in
CD11cþ BMDCs/LCL-BMDCs, as well as LCs.
BMDCs generated from p14-deficient mice reveal decreased
expression of TGFbRII and diminished surface binding of TGFb1
Owing to the decreased sensitivity of p14-deficient BMDCs
toward TGFb1, we asked whether the surface expression of
TGFb1-binding receptors was altered in p14-deficient
BMDCs. Indeed, FACS analysis of the TGFbRII subunit
revealed a decreased expression level of this receptor on
immature CD11cþCD86 and mature CD11cþCD86þ p14-
deficient BMDCs (Figure 5a). For direct analysis of the binding
capacity of TGFb1 to cell surface receptors, we incubated
BMDCs on day 8 of culture with biotinylated TGFb1 followed
by a fluoresceinated avidin detection reagent. CD11c-p14del
BMDCs bound significantly less TGFb1 as compared
with control cells, indicated by the reduced mean fluores-
cence intensity of TGFb1 staining measured by flow cytome-
try. This held true for BMDC cultures in the absence and
presence of additional TGFb1 (Figure 5b and c). The reduced
TGFb1 binding of BMDCs from TGFb1-containing cultures,
as compared with nonsupplemented cultures, was
presumably caused by saturation and/or internalization of
TGFb receptors. Microscopic analysis further emphasized
our flow cytometry data, as p14-deficient BMDCs exhibited
reduced fluorescence intensity when incubated with fluores-
cent TGFb1 (Figure 5d).
Diminished TGFbRII expression on epidermal LCs from Langerin-
p14del mice
For direct assessment of TGFb surface receptor expression on
LCs, we used LCs isolated from newborn skin of 21-day-old
Langerin-p14del and control mice. Antibody staining of
TGFbRII revealed significantly reduced expression on Lan-
gerin-p14del as compared with control LCs (Figure 6a and b).
In the light of recent publications demonstrating that LC
homeostasis is impaired by deficient IL-34 signaling (Greter
et al., 2012; Wang et al., 2012), we analyzed the expression of
the IL-34 receptor, i.e., the M-CSF receptor (CD115), on p14-
deficient BMDCs and LCs (Supplementary Figure S3 online).
However, we could not detect any differences in the expres-
sion of the M-CSF receptor between p14-deficient and control
BMDCs/LCs (Supplementary Figure S3 online). In addition, we
did not observe alterations in the expression of the GM-CSFR
(CD116), a receptor that has also been implicated in the
regulation of LC homeostasis and maturation (Burnham et al.,
2000) (Supplementary Figure S3 online). Thus, p14 deletion
negatively regulates the expression of TGFbRII by LCs.
DISCUSSION
Several reports have demonstrated a pivotal role of the late
endosomal adaptor molecule p14 in fundamental cellular
processes such as cell proliferation, growth factor signaling,
and endosomal rearrangement in nonimmune but also
immune cells (Teis et al., 2006; Taub et al., 2012). Analysis
of the molecular mechanism underlying these processes
revealed a protein complex called LAMTOR, which consists
of five molecules: p18 (LAMTOR1), p14 (LAMTOR2), MP1
(LAMTOR3), HPXIP (LAMTOR4), and C7orf59 (LAMTOR5).
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Recruitment and assembly of the LAMTOR complex at the
stage of multivesicular bodies and lysosomes represents a
prerequisite for the subsequent, spatiotemporal activation of
the ERK MAPK cascade (Wunderlich et al., 2001; Teis et al.,
2002; Nada et al., 2009), as well as the mTOR cascade
(Sancak et al., 2010; Bar-Peled et al., 2012). In our previous
work, we demonstrated that CD11c-mediated deficiency of
p14 has a profound impact on the population of epidermal-
resident LCs resulting in a complete loss of LCs in adult mice
owing to apoptosis and cell cycle arrest. Moreover, we were
able to establish that p14 deletion critically affects signaling of
the LAMTOR complex through the ERK MAPK and mTOR
cascade in DCs (Sparber et al., 2014).
In this study, we extended our findings in the CD11c-p14del
mice and investigated additional effects of p14 deficiency
specifically in LCs. To this end, we deleted p14 under the
control of the langerin promoter. Similar to CD11c-p14del
mice, langerin-specific ablation of p14 results in a gradual
loss of LCs starting approximately 3 weeks after birth. Impor-
tantly, we noticed divergent kinetics for the disappearance of
LCs in CD11c-p14del and Langerin-p14del mice, with a
delayed loss of LCs in the latter. A possible explanation for
this discrepancy is the temporally distinctive activation of the
cd11c and langerin promoters during neonatal LC develop-
ment. The expression of CD11c is quickly induced on LCs in
the epidermis of newborn mice between days 0 and 4 (Chorro
et al., 2009 and Supplementary Figure S1 online), indicating a
very rapid activation of the CD11c promoter. In contrast,
Langerin can be detected earliest by day 5 after birth in about
half of the LCs, and only by days 7–10 most LCs express
Langerin (Tripp et al., 2004 and Supplementary Figure S1
online). In contrast to CD11c-p14del mice in which both
Langerin-expressing skin DC subsets were reduced (Sparber
et al., 2014), deletion of p14 using Langerin-Cre mice affected
only LCs but not Langerinþ dermal DCs. The p14 molecule
interferes with many different cellular mechanisms in LCs, e.g.,
cell cycle arrest and apoptosis, and some of these effects may
also affect Langerinþ dermal DCs upon p14 deletion.
However, this was not investigated in further detail in this
study and remains elusive. Interestingly, in the Langerin-p14del
mice, the population of Langerinþ dermal DCs seems
unaltered, which may be caused by the delayed activation of
the langerin promoter and the faster turnover and repopulation
kinetics of Langerinþ dermal DCs (Bursch et al., 2007;
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Ginhoux et al., 2007; Poulin et al., 2007) when compared with
LCs (Noordegraaf et al., 2010). In combination, this will lead
to a postponed deletion of p14 under the langerin promoter
and a fast replacement by new p14-sufficient dermal
Langerinþ DCs, which together might conceal the p14-
driven loss of this population observed in the skin of CD11c-
p14del mice (Sparber et al., 2014).
During the past decade, the functional role of LCs has
been disputed because of the fact that the three mouse
models allowing depletion of Langerinþ dermal DCs and/or
LCs (Bennett et al., 2005; Kaplan et al., 2005; Kissenpfennig
et al., 2005) yielded conflicting results, particularly in the
CHS model (Romani et al., 2010). Hence, we performed
CHS assays with the contact sensitizer TNCB in adult
Langerin-p14del mice completely lacking LCs and observed a
reduced CHS response. Although this is in contrast to a
possible regulatory function of LCs in CHS (Kaplan et al.,
2005; Bobr et al., 2012), our finding provides further evidence
CD11c+ BMDCs CD11c+CD86– CD11c+CD86+
CD11c+CD86low BMDCs
CD11c+CD86high BMDCs
CD11c-p14del
CD
11
c-
p1
4 d
el
Negative control:
biotin-soy protein
Negative control:
pre-inc. with
anti-TGFβ1
Negative control: pre-inc. with anti-TGFβ1Control mice: biotin-TGFβ1
Control mice:
biotin-TGFβ1
CD11c-p14del mice:
biotin-TGFβ1
CD11c-p14del mice: biotin-TGFβ1
Control: mice:
biotin-TGFβ1
Cu
ltu
re
 w
/o
 T
G
Fβ
1
Cu
ltu
re
 w
ith
 T
G
Fβ
1
CD11c-p14del mice:
biotin-TGFβ1
BMDC culture
w/o TGFβ1
0
Co
ntr
ol
CD
11
c-p
14 d
el
Co
ntr
ol
CD
11
c-p
14 d
el
10
20
M
FI
 o
f T
G
Fβ
1 
(su
rfa
ce
)
M
FI
 o
f T
G
Fβ
1 
(su
rfa
ce
)
30
40
0
10
20
30
40
BMDC culture
with TGFβ1
Control
Co
nt
ro
l
100
100
47.5
52
0 200 400
FSC-H
CD11c
600
0.48 27.4 0.9 62.9
27.98.2961.610.6
0.37 29.6
56.113.9
800 1,000
0 200 400
FSC-H
600 800 1,000
101
101
102
102
TGFβRII
CD
11
c
CD
11
c
%
 O
f m
ax
CD
86
103
103
83
a
b
d
c
74.4 52.6
47.1
104
100
101
102
103
104
100
101
102
103
104
CD
86
100
101
102
103
104
104 100 101 102
TGFβRII
103 104 100 101 102
TGFβRII
103 104 100 101 102
TGFβRII
103 104
100 101 102
TGFβRII
103 104100 101 102
TGFβRII
103 104100 101 102
TGFβRII
103 104100 101 102
TGFβRII
103 104
TG
Fβ
1
100
101
102
103
104
TG
Fβ
1
100
101
102
103
104
TG
Fβ
1
100
101
102
103
104
TG
Fβ
1
100
101
102
103
104
TG
Fβ
1
100
101
102
103
104
TG
Fβ
1
100 101 102 103 104
CD11c
100 101 102 103 104
CD11c
100 101 102 103 104
TGFβ1
100 101 102 103 104
0
20
40
60
%
 O
f m
ax
80
100
0
20
40
60
%
 O
f m
ax
80
100
0
20
40
60
%
 O
f m
ax
80
100
0
20
40
60
%
 O
f m
ax
80
100
0
20
40
60
%
 O
f m
ax
80
100
0
20
40
60
%
 O
f m
ax
80
100
0
20
40
60
80
100
CD11c-p14del
Control
0.21 5.6
81.612.5
2.24 47
24.126.7
0.44 29.1
43.427.1
100
101
102
103
104
TGFβ1
100 101 102 103 104
CD11c
100 101 102 103 104
CD11c
100 101 102 103 104
CD11c
100 101 102 103 104
0
20
40
60
%
 O
f m
ax
80
100
Figure 5. Ablation of p14 reduces the expression of transforming growth factor bRII (TGFbRII) and the surface binding of TGFb1 to bone marrow–derived
dendritic cells (BMDCs). (a) Analysis of CD11cþ BMDCs, obtained from CD11c-p14del and control mice, on day 8 of culture for the expression of the TGFbRII.
BMDCs were analyzed by discriminating between CD11cþCD86 and CD11cþCD86þ BMDCs. (b, c) Binding of biotinylated TGFb1 to day 8 CD11cþ BMDCs
cultured without (upper row) or with TGFb1 (lower row); isotype, gray filled; control mice, dotted line; CD11c-p14del mice, black line. Biotinylated soy protein
or preincubation with an anti-TGFb1 blocking antibody was used for negative controls. One representative experiment of each BMDC culture condition in
a and b, combined data from four individually analyzed mice per genotype and culture condition in c. Mean±SD is shown. (d) Microscopic analysis of (green
fluorescent) TGFb1 surface binding on day 8 CD11c-p14del and control BMDCs. Preincubation with an anti-TGFb1 blocking antibody was used as negative
control. Scale bar¼ 10mm. *Po0.05.
F Sparber et al.
The Endosomal Adaptor p14 Affects TGFb1 Pathway in Langerhans Cells
www.jidonline.org 125
for a role of LCs in the efficient induction of CHS, which is in
line with several reports suggesting that both LCs and
Langerinþ dermal DCs contribute to CHS induction
(Bennett et al., 2005, 2007; Bursch et al., 2007; Edelson
et al., 2010; Honda et al., 2010; Kel et al., 2010; Noordegraaf
et al., 2010; Zahner et al., 2011). Thus, in the case of
Langerin-p14del mice, the attenuated CHS reaction may be
due to the lack of LCs or, alternatively, to functional
alterations of Langerinþ dermal DCs. However, we have
not further explored the latter possibility in Langerin-p14del
mice in this study.
In our prior work, we established that various signal
transduction molecules involved in the mTORC1 pathway
are significantly reduced in p14-deficient BMDCs (Sparber
et al., 2014). Here, we take this finding a step further and
demonstrate that the differentiation of LCL-BMDCs is
compromised upon deletion of p14. To a certain extent, this
is reminiscent of previous work, showing that CD11c-specific
deletion of the mTORC1-related molecule RAPTOR leads to
the loss of LCs in situ (Kellersch and Brocker, 2013).
However, comparison of the LC phenotype of RAPTOR-
deficient and CD11c-/Langerin-p14del mice reveals several
differences. Most prominently, the enhanced maturation of
p14-deficient LCs is not observed in RAPTOR-deficient LCs.
As TGFb1 is essential for maintaining the LCs in an immature
state in the skin (Kel et al., 2010; Bobr et al., 2012), we
examined the effect of TGFb1 on p14-deleted BMDCs.
Moreover, the development of LCs is critically influenced
by TGFb1 (Borkowski et al., 1996; Kaplan et al., 2007), and
LC-like cells can be generated in vitro in cultures
supplemented with TGFb1 (Strobl et al., 1997; Yamaguchi
et al., 1997; Geissmann et al., 1998; Caux et al., 1999).
Indeed, we observed an impaired differentiation of LCL-
BMDCs from bone marrow of CD11c-p14del mice in vitro.
This was accompanied by higher expression of MHC-class II,
CD86, and CD40 indicative of enhanced maturation of
CD11c-p14del as compared with control BMDCs even in
the presence of exogenous TGFb1. This finding suggests that
p14 expression is essential for the responsiveness of BMDCs
toward TGFb1 that would keep these cells in an immature
state. In fact, the increased maturation in p14-deleted BMDC
mirrors the LC phenotype observed in Langerin-p14del mice
in situ, as well as in mice with a LC-specific deletion of the
TGFb receptor 1 (ALK5) (Kel et al., 2010).
Previous work already demonstrated that deletion of p14
led to an impaired endosomal sorting of the EGFR (Teis et al.,
2006), and thus it is conceivable that p14 deficiency might
also affect other growth factor receptors such as TGFb
receptors. In line, we detected a reduced surface binding of
TGFb1 to p14-deficient BMDCs and less surface expression of
TGFbRII on ex vivo–isolated LCs. However, to date, there is
no causal link established between the adaptor molecule p14
and the TGFb pathway. Whether p14 deletion in LCs directly
affects TGFb receptors by disrupting receptor shuttling
processes, or whether the decrease of TGFb receptors is
rather an indirect response to the p14 deletion, remains
elusive. Previous publications demonstrated that other
receptors such as the IL-34-binding M-CSFR (Greter et al.,
2012; Wang et al., 2012) and the GM-CSFR (Burnham et al.,
2000) are important for the homeostasis and maturation of LCs
in situ. However, FACS analysis did not reveal any differences
in M-CSFR and GM-CSFR cell surface expression between
p14-deficient and p14-sufficient BMDCs and LCs.
Taken together, ablation of p14 under control of the
langerin promoter leads to a gradual but delayed loss of LCs
as compared with CD11c-p14del mice owing to increased
apoptosis and cell cycle arrest of LCs in the epidermis (Sparber
et al., 2014). The hyporesponsiveness to TGFb1 as observed in
CD11c-/Langerin-p14del mice might enable enhanced
apoptosis, as TGFb1 and apoptosis have been linked; e.g.,
TGFb1 can inhibit apoptosis through the MAPK pathway (Park
et al., 2005, Ohtani et al., 2009). The enhanced maturation of
LCs can be ascribed to the insensitivity of p14-deficient cells
to TGFb1 present in the skin, most probably caused by
reduced TGFb receptor expression on the surface of LCs.
Thus, the discovery that p14 deletion affects the TGFb1
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pathway, besides the already known defects in ERK and
mTOR signaling, adds an important aspect to the molecular
mechanisms that control LC homeostasis in vivo. Hence, the
published study on CD11c-/Langerin-p14del mice (Sparber
et al., 2014) and the data presented here are complementary
and the finding that the TGFb1 pathway is disturbed in the
p14-deficient cells represents an additional explanation as to
how the maintenance of immature LCs, as well as their
differentiation, are affected in these mice.
MATERIALS AND METHODS
Mice
The following mice were used: Langerin-Cre (Zahner et al., 2011),
CD11c-Cre (Caton et al., 2007), and p14-flox mice (Teis et al., 2006).
Langerin-Cre or CD11c-Cre mice were crossed to p14-flox mice to
generate LC- or DC-specific p14-deficient mice: Langerin-Cre/p14flox/flox
and CD11c-Cre/p14flox/flox (Langerin-p14del/CD11c-p14del). All mice
were used at 6–8 weeks of age for experiments with adult mice or
younger, as indicated in newborn skin analyses. Mice were bred at
the animal facility of the Department of Dermatology and Venereol-
ogy. All experimental protocols were approved by the Austrian
Federal Ministry of Science and Research and performed according
to institutional guidelines.
PCR genotyping
DNA was isolated from the tail of mice using Qiagen TailLysis Buffer
(Qiagen, Venlo, The Netherlands). Appropriate primers (Microsynth,
Balgach, Switzerland) and analysis of particular genetic loci were
used, as described previously (Teis et al., 2006), in order to identify
CD11c-p14del/Langerin-p14del mice.
Flow cytometry
All antibody-staining steps were performed for 15minutes at 4 1C.
Nonspecific FcR-mediated antibody staining was blocked by incuba-
tion with anti-CD16/32 Ab (2.4G2, prepared in-house from hybridoma
supernatant). The following antibodies were used: anti-Langerin-Alexa
488 (929.F3, Dendritics, Lyon, France); anti-MHC-class II-FITC
(553632), anti-CD86-PE (553692), anti-CD40-PE (55379), and anti-
CD103-PE (557495) (all from BD Biosciences, Vienna, Austria); anti-
CD11c-PE-Cy5.5 (15-0114-81), anti-MHC-class II-APC (17-5321-81),
and anti-M-CSFR-APC (17-1152-82, all from eBioscience, San Diego,
CA); APC-coupled Life/Dead Cell stain kit (L10120, Life Technologies,
Carlsbad, CA); and unconjugated anti-TGFbRII (sc-400) and anti-GM-
CSFR alpha (sc-25472, both from Santa Cruz Biotechnology,
Santa Cruz, CA). The secondary antibody Alexa fluor488 goat anti-
rabbit IgG was used to detect anti-TGFbRII and anti-GM-CSFR
antibodies (A31628, Life Technologies). TGFb-binding assays were
carried out using the TGFb1 Fluorokine Kit (NFTG0, R&D Systems,
Minneapolis, MN) according to the manufacturer’s guidelines. For
Annexin-V staining, the Annexin-V-FITC Apoptosis Detection Kit
(BMS500FI/300, from eBioscience) was used. Flow cytometry was
performed on a BD Biosciences FACSCalibur or BD Biosciences
Canto with data analysis using the FlowJo software (Tree Star, Olten,
Switzerland).
LN cell suspensions
Skin-draining LNs (brachial, inguinal, and auricular) were teased
apart and digested (25minutes/37 1C) with 0.12mgml–1 of DNAse I
(Roche, Mannheim, Germany) and 0.5mgml–1 collagenase D
(Roche). The resulting cell suspension was used for antibody labeling
and subsequent flow cytometric analysis.
Skin cell suspensions
For epidermal cell suspensions, ear and trunk skin were floated on
0.8% trypsin (Merck, Darmstadt, Germany) for 15–45minutes at 37 1C,
respectively (Stoitzner et al., 2010). For digestion of total skin, trunk
skin was cut into small pieces and transferred into Hank’s medium (w/
o Ca2þMg2þ , Biochrom AG, Berlin, Germany), supplemented with
0.15mgml–1 Liberase (Roche) and 0.12mgml–1 DNAse I (Roche) for
1hour at 37 1C.
Epidermal sheets
Epidermis was separated from the dermis using 0.1M ammoniumthio-
cyanate (Merck). The epidermis was peeled off and fixed in acetone
(Sigma-Aldrich, Vienna, Austria) or 4% paraformaldehyde (SAV-LP,
Flintsbach, Germany). LCs in situ were stained with an antibody for
MHC-class II (2G9-FITC, BD Biosciences).
CHS assay
Two-month-old Langerin-p14del and littermate control mice were
sensitized (day 0) by applying 100ml of 1% (high dose) or 0.5% (low
dose) TNCB (dissolved in acetone: olive oil vehicle, at a ratio of 4:1)
onto the shaved abdominal skin. Five days later, the sensitized mice
were challenged by applying 25ml of either 0.5% (high dose) or
0.25% (low dose) TNCB onto the dorsal side of the right ear. As a
control, the left ear of the mice was treated with the vehicle only.
After 24hours, the ear thickness was measured. The actual ear
swelling was calculated by subtracting ear thickness of the vehicle-
treated ear from the TNCB-treated ear.
BMDCs/TGFb1 blocking assay
Bone marrow was isolated from the hind limbs (femur and tibia).
Erythrocytes were removed using an ammonium chloride buffer.
Unfractionated bone marrow cells were cultured in complete med-
ium (RPMI-1640 supplemented with 10% fetal calf serum, 2mM L-
glutamine, and 50mgml–1 gentamycin (all from PAA, GE Healthcare,
Vienna, Austria) containing 20ngml–1 of GM-CSF (14-8332-62,
eBioscience) for 8 days. LCL-BMDCs were obtained by culturing
unfractionated bone marrow in complete medium supplemented with
20ngml–1 GM-CSF and 5ngml–1 human TGFb1 (100-21C, Pepro-
Tech, Hamburg, Germany) for 8 days (Valladeau et al., 2002).
Statistics
Data were analyzed with unpaired Student’s T-test or one- or two2-
way analysis of variance with post-hoc test (Bonferroni or Tukey’s
test). P-values o0.05 were considered significant (*), values o0.01
were considered very significant (**), and values o0.001 were
considered highly significant (***). Statistics were performed using
PRISM 5.0 (Graphpad Software, La Jolla, CA).
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